This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at bakerdan@wsu.edu.
Use on intact skin in adults to provide local analgesia for superficial aesthetic procedures, such as dermal filler, injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal.
Rivaroxaban
Xarelto (Janssen Pharmaceuticals)
Treatment of deep vein thrombosis or pulmonary embolism and to reduce the risk of recurrent deep venous thrombosis and pulmonary embolism following initial treatment 
WARNINGS AND PRECAUTIONS Hepatitis B Virus (HBV) Reactivation
Use of tumor necrosis factor (TNF) blockers has been associated with reactivation of HBV in patients who are chronic carriers of this virus. In some instances, HBV reactivation occurring in conjunction with TNF blocker therapy has been fatal. The majority of reports have occurred in patients concomitantly receiving other medications that suppress the immune system, which may also contribute to HBV reactivation. 
WARNINGS and PRECAUTIONS Mortality and Coronary Heart Disease Morbidity
The effect of Fenoglide on coronary heart disease morbidity and mortality and noncardiovascular mortality has not been established.
Skeletal Muscle
Observational studies indicate that the risk for rhabdomyolysis is increased when fibrates, in particular gemfibrozil, are co-administered with an HMG-CoA reductase inhibitor (statin). The combination should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.
Paradoxical Decreases in High-Density Lipoprotein (HDL) Cholesterol Level
Reports of severe decreases in HDL cholesterol levels (as low as 2 mg/dL) occurring in diabetic and nondiabetic patients initiated on fibrate therapy. The decrease in HDL cholesterol is mirrored by a decrease in apolipoprotein A1.
DRUG INTERACTION Colchicine
Cases of myopathy, including rhabdomyolysis, have been reported with fenofibrates co-administered with colchicine, and caution should be exercised when prescribing fenofibrate with colchicine. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm327867.htm (continued) In pregnant cynomolgus monkeys treated with ipilimumab every 3 weeks from the onset of organogenesis in the first trimester through parturition, at exposure levels either 2.6 or 7.2 times higher by area under the curve (AUC) than the exposures at the clinical dose of 3 mg/kg of ipilimumab, found no treatmentrelated adverse effects on reproduction during the first 2 trimesters of pregnancy. Beginning in the third trimester, the ipilimumab-treated groups experienced higher incidences of severe toxicities including abortion, stillbirth, and premature delivery (with corresponding lower birth weight) and higher incidences of infant mortality in a dose-related manner compared to controls.
Nursing Mothers
In monkeys treated at dose levels resulting in exposures 2.6 and 7.2 times higher than those in humans at the recommended dose, ipilimumab was present in milk at concentrations of 0.1 and 0.4 mcg/mL, representing a ratio of up to 0.3% of the serum concentration of the drug. Because many drugs are secreted in human milk and because of the potential for serious adverse reactions in nursing infants from Yervoy, a decision should be made whether to discontinue nursing or to discontinue Yervoy, taking into account the importance of Yervoy to the mother. 
CONTRAINDICATIONS
Starting these drugs in a patient who is being treated with linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome.
WARNINGS Serotonin Syndrome
The development of a potentially life-threatening serotonin syndrome has been reported with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). These drugs should not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm327699.htm a Practitioners are encouraged to check the FDA's MEDWATCH Web site (http://www.fda.gov/medwatch/safety.htm) for updated information.
